Stroke, IschemicNCT07118345
Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial
A study testing Early prophylactic decompressive hemicraniectomy in people with Stroke, Ischemic and Cerebral Edema, run by Xuanwu Hospital, Beijing at 2 sites in China.
Trial summary
Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Stroke, Ischemic, Cerebral Edema
- What is being tested?
- Early prophylactic decompressive hemicraniectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 380 participants
- Where
- 2 sitesChina
- Study dates
- 19 Jul 2025to 19 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Clinical Exclusion Criteria
- Any symptoms and signs of brain herniation before randomization, such as pupil anisocoria and unstable vital signs.
- In the judgment of the investigator, the subject is likely to have supportive care withdrawn in the first day.
- Commitment to decompressive hemicraniectomy (DHC) prior to enrollment.
- Severe, sustained hypertension (systolic blood pressure > 220 mm Hg or diastolic blood pressure > 110 mm Hg);
- Baseline blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L);
Show all 20Show fewer
- Baseline platelet count <100 x10^9/L;
- Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with international normalized ratio > 1.7;
- Severe renal insufficiency, defined as serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate [GFR] < 30 ml/min, or patients requiring hemodialysis or peritoneal dialysis;
- Patients that cannot complete 90-day follow-up (such as no fixed residence, overseas patients, etc.);
- Suspected vasculitis or septic embolism;
- Neurological diseases or mental disorders before onset that affect the assessment of the condition;
- Females who are pregnant or in lactation;
- Participating in other clinical trials that could confound the evaluation of the study;
- Subjects who, in the opinion of the investigator, have a life expectancy <3 months due to conditions not related to current LHI or are unlikely to comply with follow-up requirements. Other conditions that the investigators believe are not suitable for participation or may pose a significant risk to the patient.
- Neuroimaging Exclusion Criteria
- Evidence of other brain diseases such as cerebral trauma, intracranial tumor (except small meningioma), cerebral aneurysm, etc.
- Evidence of acute ischemic infarction in bilateral anterior circulation territory or involvement of posterior circulation territories (other than in patients with a fetal or near-fetal PCA configuration);
- Vascular perforation during thrombectomy;
- The pre-randomization CT findings exhibits evidence of parenchymal hemorrhage 2 intracranial hemorrhage, diffuse severe subarachnoid hemorrhage, or intraventricular hemorrhage. Patients with localized mild subarachnoid hemorrhage, hemorrhagic infarction type1 or 2, and small parenchymal hematoma type 1 without midline shift may be included;
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Not yet recruiting
Xuanwu Hospital, Capital Medical University.
Beijing
Liqun Jiao, MD., 86+13911224991, jiaoliqun@xwhosp.org
- Recruiting
Liaocheng Brain Hospital
Shandong
Liyong Zhang, MD., 86+13346256936, 13346256936@163.com
About this study
Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting ~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (<7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients >60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist:
DHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early/Prophylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is ~50% and outcomes are dismal despite recanalization.
Study Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.
- Conditions
- Stroke, Ischemic, Cerebral Edema
- Being tested
- Early prophylactic decompressive hemicraniectomy
- Keywords
- Acute Ischemic Stroke, Endovascular Thrombectomy, Cerebral Edema, Hemicraniectomy
- Medical subject headings
- Ischemic Stroke, Brain Edema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early prophylactic decompressive hemicraniectomyProcedure or surgery
Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Early prophylactic decompressive hemicraniectomy Receives: Procedure: Early prophylactic decompressive hemicraniectomy |
| Control group | No intervention | Standard medical treatment (with or without rescue decompressive craniectomy if needed). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of mRS score of 0-4
Rate of mRS score of 0-4
Measured: 90 days (±7 days) after randomization
Secondary outcomes (16)
Rate of mRS score of 0-3 Ordinal shift analysis of mRS •Rate of mRS score of 0-2 •Rate of midline shift ≥ 5 mm •Rate of brain herniation Improvement of the NIHSS Rate of neurological deterioration Rate of rescue decompressive hemicraniectomy
mRS score ranges 0-6
Measured: 90 days (±7 days) after randomization
Ordinal shift analysis of mRS
mRS score ranges 0-6
Measured: 90 days (±7 days) after randomization
Rate of mRS score of 0-2
mRS score ranges 0-6
Measured: 90 days (±7 days) after randomization
Rate of midline shift ≥ 5 mm
Based on imaging assessment (e.g., CT, MRI)
Measured: Within 72 hours after randomization
Rate of brain herniation
e.g., 1 or 2 dilated, fixed pupils; unconsciousness related to edema [i.e., ≥2 on item 1a on the NIHSS]; and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator's judgment
Measured: Within 72 hours after randomization
Improvement of the NIHSS
The NIHSS score range from 0 (no deficit) to 42 (maximum deficit)
Measured: 5-7 days after randomization or discharge
Rate of neurological deterioration
Defined as increase of NIHSS score ≥4 from baseline
Measured: 5-7 days after randomization or discharge
Rate of rescue decompressive hemicraniectomy
Control group
Measured: 5-7 days after randomization or discharge
Length of ICU stay
Residual stay days of ICU
Measured: Perioperative
Length of hospitalization
Residual stay days of hospitalization
Measured: Perioperative
Barthel Index
The Barthel Index range from 0 (severe disability) to 100 (no disability)
Measured: 90 days (±7 days) after randomization
Modified Rankin scale and Barthel Index
The mRS score range from 0 (no disability) to 6 (death), the Barthel Index range from 0 (severe disability) to 100 (no disability)
Measured: 12 months (±30 days) after randomization
Rate of any intracranial hemorrhage (ICH)
The occurrence of ICH includes the following scenarios:
- new occurrence of ICH;
- progression of ICH based on Heidelberg Bleeding Classification.
Measured: Within 72 hours after randomization
Rate of parenchymal hematoma type 2 intracranial hemorrhage
Measured: Within 72 hours after randomization
Mortality
Defined as mRS 6
Measured: 90 days (±7 days) after randomization
Serious Adverse Events
Detailled description noted in study protocol
Measured: 90 days (±7 days) after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2025
- Study start19 Jul 2025
- Primary completion19 Jun 2029 (estimated)
- Study completion19 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke, IschemicStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 380 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07118345
- Sponsor's protocol ID
- IAT-EPIC
- Status last verified
- Aug 2025
- First submitted
- 29 Jun 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial
- ClinicalTrials.gov ID
- NCT07118345
- Acronym / sponsor ID
- IAT-EPIC
- Conditions
- Stroke, Ischemic, Cerebral Edema
- Keywords
- Acute Ischemic Stroke, Endovascular Thrombectomy, Cerebral Edema, Hemicraniectomy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 380 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Study start
- 19 Jul 2025 (actual)
- Primary completion
- 19 Jun 2029 (estimated)
- Study completion
- 19 Jun 2029 (estimated)
- First posted
- 12 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting ~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (<7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients >60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist:
DHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early/Prophylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is ~50% and outcomes are dismal despite recanalization.
Study Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Procedure: Early prophylactic decompressive hemicraniectomyEarly prophylactic decompressive hemicraniectomy |
| Control group | No intervention | –Standard medical treatment (with or without rescue decompressive craniectomy if needed). |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (20 listed)
- Clinical Exclusion Criteria
- Any symptoms and signs of brain herniation before randomization, such as pupil anisocoria and unstable vital signs.
- In the judgment of the investigator, the subject is likely to have supportive care withdrawn in the first day.
- Commitment to decompressive hemicraniectomy (DHC) prior to enrollment.
- Severe, sustained hypertension (systolic blood pressure > 220 mm Hg or diastolic blood pressure > 110 mm Hg);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early prophylactic decompressive hemicraniectomyEarly prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization). | Procedure or surgery | Experimental group |
Primary outcome
Rate of mRS score of 0-4
Time frame: 90 days (±7 days) after randomization
Rate of mRS score of 0-4
16 secondary outcomes
Rate of mRS score of 0-3 Ordinal shift analysis of mRS •Rate of mRS score of 0-2 •Rate of midline shift ≥ 5 mm •Rate of brain herniation Improvement of the NIHSS Rate of neurological deterioration Rate of rescue decompressive hemicraniectomy
Time frame: 90 days (±7 days) after randomization
Ordinal shift analysis of mRS
Time frame: 90 days (±7 days) after randomization
Rate of mRS score of 0-2
Time frame: 90 days (±7 days) after randomization
Rate of midline shift ≥ 5 mm
Time frame: Within 72 hours after randomization
Rate of brain herniation
Time frame: Within 72 hours after randomization
Improvement of the NIHSS
Time frame: 5-7 days after randomization or discharge
Rate of neurological deterioration
Time frame: 5-7 days after randomization or discharge
Rate of rescue decompressive hemicraniectomy
Time frame: 5-7 days after randomization or discharge
Length of ICU stay
Time frame: Perioperative
Length of hospitalization
Time frame: Perioperative
Barthel Index
Time frame: 90 days (±7 days) after randomization
Modified Rankin scale and Barthel Index
Time frame: 12 months (±30 days) after randomization
Rate of any intracranial hemorrhage (ICH)
Time frame: Within 72 hours after randomization
Rate of parenchymal hematoma type 2 intracranial hemorrhage
Time frame: Within 72 hours after randomization
Mortality
Time frame: 90 days (±7 days) after randomization
Serious Adverse Events
Time frame: 90 days (±7 days) after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
Related trials for Stroke, Ischemic
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Early prophylactic decompressive hemicraniectomy in people with Stroke, Ischemic and Cerebral Edema, run by Xuanwu Hospital, Beijing at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of mRS score of 0-4 (time frame: 90 days (±7 days) after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.